Ivonescimab trials for Lung cancer

All Ivonescimab trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Ivonescimab for Lung cancer

• A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
  NCT07623356 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
  NCT07535437 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of Ivonescimab in First-Line ES-SCLC
  NCT07245446 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
  NCT07594522 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
  NCT07619339 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
  NCT07208773 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
  NCT06840834 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
  NCT06868732 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
  NCT07405190 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
  NCT07359040 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
  NCT06769971 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
  NCT07397338 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
  NCT06951646 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 20 locations

Common questions

How many trials study Ivonescimab for Lung cancer?

13 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.